Pneumococcal Vaccine Linked to Better COVID-19 Outcomes in IRD Patients: Study
Researchers have found in a new study that Pneumococcal vaccination was associated with fewer hospitalizations and a milder course of COVID-19 in individuals with inflammatory rheumatic diseases (IRD), suggesting a protective effect beyond its primary purpose.
It has been suggested that vaccinations could induce a trained immunity able to decrease COVID-19 severity. Our primary aim was to evaluate the COVID-19 severity among patients with inflammatory rheumatic diseases (IRD) vaccinated against pneumococcus and influenza compared to those not vaccinated. A secondary objective was also to determine They conducted a longitudinal study within the French administrative and medical data base (SNDS). We have identified patients with one following of these IRD: rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PsA). COVID-19 infected patients were identified using CIM-10 code and vaccination status was extracted from the database. Results: 406,156 patients were identified, with 64.6 % women and a mean age of 62.2 years. Pneumococcal and influenza vaccination rate in this population were respectively 37.8 % and 40.5 %. We recorded 0.9 % COVID-19 hospitalizations (n = 3574), 0.24 % severe infections (n = 980), and 0.17 % deaths (n = 697). Multivariate analysis demonstrated pneumococcal vaccination's association with decreased risks of hospitalization (OR 0.84 IR95 %[0.78–0.91] p < 0.0001), severe COVID-19 forms (OR 0.83 IR95 %[0.72–0.96] p < 0.05), and death (OR 0.82 IR95 %[0.70–0.97] p < 0.05), while influenza vaccination associated with increased risks of these outcomes (OR 1.47 IR95 %[1.36–1.58] p < 0.0001, OR 1.54 IR95 %[1.33–1.78] p < 0.0001, OR 1.62 IR95 %[1.36–1.93] p < 0.0001, respectively). Pneumococcal vaccination was associated with a reduced hospitalization rate, and occurrence of severe forms of COVID-19, including death, among infected patients. These findings suggest the possible involvement of vaccine-induced trained immunity in shaping the immune response to other infections especially COVID-19.
Reference:
Maxime Auroux, Thibaut Fabacher, Erik Sauleau, Laurent Arnaud, Fabienne Coury,
Pneumococcal and influenza vaccination coverage and impact on COVID-19 infection severity in patients with inflammatory rheumatic diseases: A French National Healthcare Database analysis, Vaccine, Volume 61, 2025, 127439, ISSN 0264-410X, https://doi.org/10.1016/j.vaccine.2025.127439.
(https://www.sciencedirect.com/science/article/pii/S0264410X25007364)
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.